Focal Neuroendocrine Differentiation of Conventional Prostate Adenocarcinoma As a Prognostic Factor After Radical Prostatectomy: A Systematic Review and Meta-Analysis Publisher Pubmed



Parizi MK^{1, 2} ; Iwata T^{1, 3} ; Kimura S^{1, 4} ; Janisch F^{1, 5} ; Abufaraj M^{1, 6} ; Karakiewicz PI^{7, 8} ; Enikeev D⁹ ; Rapoport LM⁹ ; Hutterer G¹⁰ ; Shariat SF^{9, 11, 12, 13}
Source: International Journal of Molecular Sciences Published:2019

Abstract

The biologic and prognostic value of focal neuroendocrine differentiation (NED) in conventional prostate adenocarcinoma (PC) patients who undergo radical prostatectomy (RP) remains controversial. In this systematic review and meta-analysis, we assessed the association of focal NED in conventional PC with oncological outcomes after RP. A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on December 2018 to find relevant studies according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We used a fixed-effect model to analyze the impact of focal NED in RP specimen on progression-free survival defined by biochemical recurrence (BCR). A total of 16 studies with the outcomes of disease progression and survival were eligible. No patient in these studies received androgen deprivation therapy prior to RP. Eleven studies found no significant correlation between focal NED and outcomes of interest, while five studies reported a significant association of focal NED assessed by immunohistochemical chromogranin A or serotonin staining with BCR or survival. Focal NED was associated with higher BCR rates after RP with a pooled HR of 1.39 (95% CI 1.07-1.81) in five studies. No heterogeneity was reported in this analysis (I2 = 21.7%, p = 0.276). In conclusion, focal NED in conventional PC is associated with worse prognosis after RP. Its presence should be reported in pathologic reports and its true clinical impact should be assessed in well-designed prospective controlled studies. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.